PreCheck Health Services, Inc. (“PreCheck” or the “Company”) (OTC: HLTY), an issuer of scientific screening devices that provide statistics to assist physicians in stopping and treating continual illnesses, introduced today that the Company has entered right into a purchase settlement with Justin and Stacey Anderson to gather JAS Practice Management, Inc. Dba JAS Consulting, Inc. And Center for Psychological Development, Inc., dba CPD Integrated Health Care. Mr. Anderson is the Company’s chief working officer and a director.
JAS Consulting is a full-carrier billing company that gives healthcare practice management, billing, and coding services to various scientific specialties to help maximize practice performance and decrease charges. CPD Integrated Health Care provides outpatient behavioral health services and number-one care in seven medical clinics in Texas and Oklahoma.
“Both acquisitions offer blessings for PreCheck and illustrate our shareholder commitment,” said Mr. Lawrence Biggs, Chief Executive Officer of PreCheck Health Services, Inc. “We agree that the billing and processing furnished using JAS Consulting may be key elements to our achievement, as they allow us to offer greater efficient services to our potential customer base of doctors and scientific practices. Furthermore, CPD’s seven clinical clinics will allow us to test additional medical screening gadgets before deploying nationally. We are confident these traits can position the Company for elevated increase and enlargement and immediately accretive for our traders.
“Upon the close of those acquisitions, all of our administrative services can be streamlined using being integrated below the PreCheck umbrella,” said Mr. Justin Anderson, Chief Operating Officer of PreCheck, and “I stay up for the increase possibilities this acquisition will offer, as both JAS Consulting and CPD Integrated Healthcare provide structures through which the trendy advances in medical technologies can be tested and validated previous to getting into the marketplace.
The phrases of the agreement include 5 million convertible preferred shares that convert to 5 million stocks of not unusual stock upon the stock trading at $2 in line with the percentage. Also, a $1 million coin consideration is paid via PreCheck at the final. Further details on the terms of this agreement are available on the
About PreCheck Health Services, Inc.
PreCheck’s present-day business distributes a clinical screening tool, the PC8B, which it purchases from the manufacturer under a personal label agreement. The PC8B scientific tool is a screening device designed to be used by physicians and scientific personnel in dealing with patient’s health. The device screens patients for biomarkers that can be precursors to certain diseases. The PC8B is designed to provide the physician with threat warning signs of a couple of fitness issues of the patient being screened.
The screening result is that the PC8B allows physicians to view records regarding certain biomarkers immediately after the screening. This can assist them in preventing continual sicknesses, including diabetes, cardiovascular disease, and many others. The PC8B is non-invasive, and combined with its ankle-brachial index check, it takes much less than 8 minutes to complete an evaluation.
Certain statements contained in this press release, consisting of, without dilemma, statements containing the words “believes,” “anticipates,” “expects,” and phrases of comparable import, represent “ahead-searching statements” in the meaning of the Private Securities Litigation Reform Act of 1995. Such ahead-looking statements involve both known and unknown risks and uncertainties.
The Company’s actual outcomes may additionally differ materially from the ones predicted in its forward-looking statements due to several things, along with our capacity to gain massive funding required for our operations, our potential to raise the cash part of the purchase charge for the acquisition of JAS Consulting and CPD Integrated Health Care, our capacity to marketplace our product to physicians, our ability to generate a gross margin from any sales we can also make; our dependence upon a sole supplier for our merchandise and our reliance of the provider to defend its
intellectual property incorporated in our product; our capacity to acquire rights to and to marketplace effectively market merchandise, which includes the PC8B, following the acquisition of JAS Consulting and CPD Integrated Health Care; our ability to increase the enterprise of these corporations; our capability to conform with relevant legal guidelines referring to the operation of scientific practice, which includes laws relating to the company exercise of drugs, and the financial relationship between PreCheck and the clinical trials it owns.
Our potential to address the dangers associated with the operation of a clinical exercise, which include claims relating to malpractice, as well as different hazards contained in “Forward-Looking Statements,” “Risk Factors,” and Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form 10-K for the 12 months ended December 31, 2018, and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in its Form 10-Q for the quarter ended March 31, 2019, and any facts contained in some other filings we make with the SEC.